X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.44
    -0.04 (-0.47%)

    Market Cap: $1.55B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(15/33)
    Avg Surprise
    -4.68%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.15 - $0.05
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$0.04+312.5%
    60d ago$0.04+312.5%
    30d ago$0.04+300.0%
    7d ago$-0.02+0.0%
    Current$-0.02
    Revenue Consensus
    $102M
    Range$100M - $102M
    6 analysts
    Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.04 - $0.10
    3 analysts
    Revenue Consensus
    $116M
    Range$114M - $119M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.02---
    Jun 26
    		$-0.01$0.02-150.00%Miss+0.0%
    Mar 26
    		$0.01$-0.01+200.00%Beat+116.7%
    Dec 25
    		$0.06$0.02+261.45%Beat+300.0%
    Sep 25
    		$0.00N/A-65.00%Miss+105.8%
    Jun 25
    		$-0.01N/A+66.67%Beat+90.0%
    Mar 25
    		$-0.06$-0.04-50.00%Miss+57.1%
    Dec 24
    		$-0.03$-0.02-50.00%Miss+70.0%
    Sep 24
    		$-0.06$-0.08+25.00%Beat+33.3%
    Jun 24
    		$-0.10$-0.09-11.11%Miss+28.6%
    Mar 24
    		$-0.14$-0.11-27.27%Miss-16.7%
    Dec 23
    		$-0.10$-0.10+0.00%Beat+0.0%
    Sep 23
    		$-0.09$-0.10+10.00%Beat+43.8%
    Jun 23
    		$-0.14$-0.11-27.27%Miss+26.3%
    Mar 23
    		$-0.12$-0.15+20.00%Beat+52.0%
    Dec 22
    		$-0.10$-0.16+37.50%Beat+76.2%
    Sep 22
    		$-0.16$-0.15-6.67%Miss+59.0%
    Jun 22
    		$-0.19$-0.22+13.64%Beat+53.7%
    Mar 22
    		$-0.25$-0.24-4.17%Miss+16.7%
    Dec 21
    		$-0.42$-0.24-75.00%Miss-2.4%
    Sep 21
    		$-0.39$-0.37-5.41%Miss-11.4%
    Jun 21
    		$-0.41$-0.30-36.67%Miss+34.9%
    Mar 21
    		$-0.30$-0.34+11.76%Beat+66.3%
    Dec 20
    		$-0.41$-0.38-7.89%Miss+66.7%
    Sep 20
    		$-0.35$-0.52+32.69%Beat+71.3%
    Jun 20
    		$-0.63$-0.73+13.70%Beat+50.8%
    Mar 20
    		$-0.89$-0.89+0.00%Beat+16.8%
    Dec 19
    		$-1.23$-1.13-8.85%Miss-25.5%
    Sep 19
    		$-1.22$-1.23+0.81%Beat-71.8%
    Jun 19
    		$-1.28$-0.94-36.17%Miss+58.3%
    Mar 19
    		$-1.07$-0.76-40.79%Miss+77.2%
    Dec 18
    		$-0.98$-0.93-5.38%Miss+24.0%
    Sep 18
    		$-0.71$-0.78+8.97%Beat+84.0%
    Jun 18
    		$-3.07$-0.88-248.86%Miss+17.4%
    Mar 18
    		$-4.69$0.00N/AMiss-1939.1%
    Dec 17
    		$-1.29$0.00N/AMiss+43.8%
    Sep 17
    		$-4.43$0.00N/AMiss-
    Jun 17
    		$-3.72$0.00N/AMiss-
    Mar 17
    		$-0.23$0.00N/AMiss-
    Dec 16
    		$-2.29$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio132.91EV/EBITDA72.64x
    Price/FCF26.20xFCF Yield3.82%
    Profitability
    Profit Margin-5.12%Operating Margin5.62%
    ROE-617.00%ROIC11.90%
    Financial Health
    Debt/Equity-25.95xInterest Coverage0.62x
    Current Ratio1.45xQuick Ratio1.02x
    Trading Statistics
    Beta0.85Avg Volume1.72M
    52-Week High$10.0852-Week Low$5.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.66
    SMA 20$8.43
    SMA 50$8.29
    SMA 200$7.02
    EMA 10$8.56
    EMA 20$8.49
    EMA 50$8.13
    EMA 200$7.17

    MACD

    Line: 0.12Signal: 0.15Hist: -0.03

    ADX

    ADX: 17.3+DI: 23.0-DI: 22.9

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down32.0
    PSAR$9.02

    Bollinger Bands

    Upper Band$9.15
    Lower Band$7.70
    %B Position1718%(Upper)
    Band Width0.51

    RSI (14-Day)

    Neutral
    50.5

    Momentum Oscillators

    Stoch %K46.9
    Stoch %D62.7
    Williams %R-73.9
    ROC (10d)-0.9%
    Momentum-0.08
    CCI (20d)-1.3
    MFI (14d)52.9

    Volatility Measures

    ATR (14d)$0.33(3.9%)
    StdDev (20d)0.36
    Hist Vol53.1%(High)

    Volume Flow

    VWAP$8.40
    OBV75.4M
    AD Line27.4M
    CMF (20d)0.134

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.8x
    VWMA (20d)$8.34

    Pivot Points

    R3$8.95
    R2$8.81
    R1$8.65
    Pivot Point$8.51
    S1$8.34
    S2$8.20
    S3$8.04

    Advanced Oscillators

    TSI10.19
    Ultimate Osc47.8
    KST41.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$92.10M$83.13M$85.81M$74.38M$71.54M$60.12M$60.10M$54.27M$48.06M$40.64M$44.39M$48.32M
    Cost of Revenue$12.51M$10.57M$10.95M$11.00M$11.90M$8.73M$9.48M$13.59M$7.79M$5.97M$15.13M$8.20M
    Gross Profit$79.59M$72.55M$74.86M$63.38M$59.64M$51.39M$50.62M$40.67M$40.27M$34.67M$29.27M$40.12M
    Operating Expenses$74.42M$64.64M$58.09M$56.65M$55.16M$54.48M$48.94M$53.57M$48.46M$48.91M$39.11M$45.03M
    R&D$10.67M$8.78M$7.87M$7.48M$8.05M$7.75M$6.09M$5.89M$5.76M$7.82M$6.38M$5.03M
    SG&A$61.03M$53.14M$47.50M$46.46M$44.39M$44.02M$40.14M$44.97M$39.99M$38.38M$37.57M$37.29M
    Operating Income$5.17M$7.92M$16.77M$6.73M$4.48M$-3,090,000$1.68M$-12,893,000$-8,187,000$-14,245,000$-9,841,000$-4,913,000
    Interest Income$1.46M$1.20M$1.46M$1.16M$948,000$1.18M$910,000$1.20M$1.29M$1.92M$1.11M$1.12M
    Interest Expense$37.73M$6.88M$7.15M$7.27M$7.36M$7.30M$7.70M$7.79M$7.96M$9.72M$7.02M$9.68M
    Income Before Tax$-31,101,000$2.23M$11.08M$621,000$-1,928,000$-9,220,000$-5,113,000$-19,062,000$-14,256,000$-18,673,000$-13,626,000$-12,527,000
    Income Tax Expense$0$0$0$0$0$0$0$-3,324,000$749,000$307,000$-236,000$-338,000
    Net Income$-31,101,000$2.23M$11.08M$621,000$-1,928,000$-9,220,000$-5,113,000$-15,738,000$-15,005,000$-18,980,000$-13,390,000$-12,189,000
    EBITDA$9.29M$12.02M$20.84M$10.76M$8.47M$897,000$5.56M$-8,738,000$-3,920,000$-7,271,000$-4,075,000$-341,000
    EBIT$5.17M$7.92M$16.77M$6.73M$4.48M$-3,090,000$1.68M$-12,473,000$-7,583,000$-10,874,000$-7,715,000$-3,964,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XERS

    News

    Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS

    Rice Hall James & Associates LLC has acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), purchasing 300,791 shares valued at approximately $2.38 million in the second quarter. The article details other institutional investors' activities, Xeris Biopharma's financial performance, and recent insider trading. Despite mixed analyst ratings, the stock has shown upward movement, but the company missed EPS estimates in its latest quarterly report.

    MarketBeat•8/19/26•
    Neutral

    Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

    Xeris Biopharma (XERS) shares rose 6.6% despite reporting wider net losses in Q2 2026, as the company tightened its full-year 2026 revenue guidance to US$385 million–US$390 million. The company's investment narrative highlights strong revenue growth potential driven by its endocrine and diabetes portfolio, but rising costs and widening losses remain a key risk. Analysts have varying forecasts, with some predicting a significant upside to the current stock price if cost pressures ease.

    Sahm•8/19/26•
    Neutral

    Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

    Xeris Biopharma Holdings (XERS) saw its stock rise 6.6% despite reporting wider net losses in Q2 2026 and for the first half of 2026. The company tightened its full-year 2026 revenue guidance to US$385 million–US$390 million, offering clearer expectations. This update, alongside recent board changes, emphasizes the ongoing challenge of rising costs outpacing revenue growth for the biopharma company.

    Simply Wall Street•8/18/26•
    Neutral

    Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues

    Xeris Biopharma Holdings (XERS) is gaining attention after tighter full-year revenue guidance and second-quarter results were released on August 6, 2026. The stock is considered 22.8% undervalued with a fair value of $11.14 per share, compared to its current price of $8.60. This valuation is supported by projected faster top-line growth, higher profit margins, and the anticipated launch of XP-8121 for hypothyroidism, despite widening losses being a concern for some.

    Sahm•8/18/26•
    Bullish

    Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

    Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted loss of $0.18 per share, missing analyst estimates.

    MarketBeat•8/15/26•
    Neutral

    Frequently Asked Questions About XERS

    Does XERS pay dividends?
    Xeris Pharmaceuticals Inc (XERS) does not currently pay a regular dividend.
    What is XERS's P/E ratio?
    Xeris Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 132.91.
    What is XERS's market cap?
    Xeris Pharmaceuticals Inc (XERS) has a market capitalization of $1.55B with a current stock price of $8.44.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In